PSC
CBIO
Prentiss Smith & Co’s Crescent Biopharma, Inc. Common Stock CBIO Stock Holding History
Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2023
Q1 | – | Sell |
-15,120
| Closed | -$45.8K | – | 65 |
|
2022
Q4 | $45.8K | Buy |
15,120
+1,120
| +8% | +$3.39K | 0.04% | 61 |
|
2022
Q3 | $8K | Hold |
14,000
| – | – | 0.01% | 62 |
|
2022
Q2 | $8K | Hold |
14,000
| – | – | 0.01% | 68 |
|
2022
Q1 | $16K | Hold |
14,000
| – | – | 0.01% | 73 |
|
2021
Q4 | $20K | Hold |
14,000
| – | – | 0.01% | 79 |
|
2021
Q3 | $31K | Hold |
14,000
| – | – | 0.02% | 75 |
|
2021
Q2 | $32K | Hold |
14,000
| – | – | 0.02% | 76 |
|
2021
Q1 | $42K | Hold |
14,000
| – | – | 0.02% | 74 |
|
2020
Q4 | $53K | Buy |
+14,000
| New | +$53K | 0.03% | 76 |
|
2019
Q4 | – | Sell |
-17,000
| Closed | -$73K | – | 64 |
|
2019
Q3 | $73K | Buy |
+17,000
| New | +$73K | 0.05% | 60 |
|
2019
Q1 | – | Sell |
-10,000
| Closed | -$95K | – | 61 |
|
2018
Q4 | $95K | Buy |
10,000
+3,000
| +43% | +$28.5K | 0.06% | 62 |
|
2018
Q3 | $101K | Hold |
7,000
| – | – | 0.06% | 85 |
|
2018
Q2 | $113K | Hold |
7,000
| – | – | 0.07% | 81 |
|
2018
Q1 | $114K | Hold |
7,000
| – | – | 0.06% | 87 |
|
2017
Q4 | $118K | Sell |
7,000
-3,000
| -30% | -$50.6K | 0.06% | 90 |
|
2017
Q3 | $140K | Hold |
10,000
| – | – | 0.08% | 73 |
|
2017
Q2 | $112K | Buy |
10,000
+3,000
| +43% | +$33.6K | 0.06% | 85 |
|
2017
Q1 | $38K | Hold |
7,000
| – | – | 0.02% | 130 |
|
2016
Q4 | $43K | Hold |
7,000
| – | – | 0.03% | 126 |
|
2016
Q3 | $50K | Sell |
7,000
-3,000
| -30% | -$21.4K | 0.03% | 120 |
|
2016
Q2 | $73K | Hold |
10,000
| – | – | 0.04% | 105 |
|
2016
Q1 | $60K | Hold |
10,000
| – | – | 0.03% | 113 |
|
2015
Q4 | $57K | Hold |
10,000
| – | – | 0.03% | 119 |
|
2015
Q3 | $56K | Hold |
10,000
| – | – | 0.03% | 112 |
|
2015
Q2 | $80K | Hold |
10,000
| – | – | 0.04% | 105 |
|
2015
Q1 | $83K | Hold |
10,000
| – | – | 0.04% | 102 |
|
2014
Q4 | $72K | Buy |
10,000
+5,000
| +100% | +$36K | 0.03% | 117 |
|
2014
Q3 | $35K | Buy |
+5,000
| New | +$35K | 0.02% | 124 |
|